Pharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over Injections

Pharvaris N.V. said a company-funded real-world analysis of hereditary angioedema management was published in Advances in Therapy. The findings highlight persistent gaps between guideline-recommended care and patients’ treatment experiences; the report excerpt provides no numerical results or quantified market implications.